PRESS RELEASE published on 05/30/2024 at 15:01, 3 months 29 days ago Press Release: Sanofi completes acquisition of Inhibrx, Inc. Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB Acquisition Nasdaq Sanofi Inhibrx SAR447537
BRIEF published on 05/27/2024 at 07:05, 4 months 1 day ago FDA Grants Priority Review to Sarclisa for Treatment of Multiple Myeloma FDA Sanofi Multiple Myeloma Sarclisa Chemotherapy
BRIEF published on 05/21/2024 at 07:35, 4 months 7 days ago Sanofi, Formation Bio, and OpenAI Announce AI Collaboration Collaboration AI Drug Development Sanofi OpenAI Formation Bio
PRESS RELEASE published on 05/21/2024 at 07:30, 4 months 7 days ago Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Sanofi, Formation Bio, and OpenAI collaborate to accelerate drug development with AI-powered software. The partnership aims to bring new medicines more efficiently Collaboration Drug Development Sanofi OpenAI Formation Bio
BRIEF published on 05/20/2024 at 22:59, 4 months 8 days ago Sanofi: April 2024 Voting Rights and Shares Information Voting Rights Shares Financial Disclosure April 2024 Sanofi
PRESS RELEASE published on 05/20/2024 at 22:54, 4 months 8 days ago Sanofi: Information concerning the total number of voting rights and shares - April 2024 Sanofi provides total number of issued shares and voting rights as per French Commercial Code and AMF regulations for April 30, 2024 Share Capital Voting Rights French Commercial Code AMF Regulations Sanofi
BRIEF published on 05/20/2024 at 20:20, 4 months 8 days ago Dupixent® Reduces COPD Exacerbations in Phase III Study FDA Clinical Study Inflammation COPD Dupixent
PRESS RELEASE published on 05/20/2024 at 20:15, 4 months 8 days ago Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM Late-breaking data from NOTUS confirm Dupixent's effectiveness in reducing COPD exacerbations and improving lung function, presented at ATS and published in NEJM COPD Dupixent NOTUS Lung Function Exacerbations
BRIEF published on 05/10/2024 at 08:05, 4 months 18 days ago Sanofi and Novavax Form Strategic Alliance to Enhance Vaccine Accessibility COVID-19 Vaccine Vaccine Development Sanofi Novavax Flu Vaccine
PRESS RELEASE published on 05/10/2024 at 08:00, 4 months 18 days ago Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Sanofi and Novavax sign co-exclusive licensing agreement to co-commercialize COVID-19 vaccine & develop flu-COVID-19 combo vaccines. Agreement enhances patient access & protection. Details in press release COVID-19 Vaccine Licensing Agreement Sanofi Novavax Flu-COVID-19
Published on 09/28/2024 at 02:06, 22 hours 18 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 22 hours 24 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 22 hours 24 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 10 hours 23 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 1 hour ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 2 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 5 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 6 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 6 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 6 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 6 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024